Jinwon Life Sciences Completes Domestic and PCT Patent Applications for COVID-19 Vaccine Composition
[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 22nd that it filed a patent for a vaccine composition including the COVID-19 vaccine (GLS-5310) currently under clinical phase 1/2a development on the 19th.
The title of the invention is a vaccine composition for the prevention of severe acute respiratory syndrome coronavirus 2 infection. The company explained, "This invention aims to enhance broad vaccine immune responses and preventive efficacy by adding proteins such as ORF3a protein in addition to the spike protein as antigens of the COVID-19 vaccine, and employs a bicistronic strategy that loads two antigens into one plasmid to promote rapid and efficient vaccine production."
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
Park Younggeun, CEO of GeneOne Life Science, said, "Using the results of the COVID-19 vaccine candidate development project utilizing the nucleic acid vaccine platform supported by the national research and development project, we have filed domestic and PCT patents. This patent application lays the foundation for securing vaccine sovereignty for COVID-19 vaccines."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
